^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Squamous Cell Carcinoma

    Related cancers:
    1d
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    2d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    2d
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation • HER-2 negative • RAS mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
    2d
    Preoperative Low Serum Basophil Levels Predict Poor Prognosis for the Patients with Esophageal Squamous Cell Carcinoma. (PubMed, Ann Thorac Cardiovasc Surg)
    Low preoperative basophil count is an independent adverse prognostic factor in ESCC. As basophil count was not correlated with C-reactive protein, it may provide prognostic value beyond conventional inflammation-based markers and could represent a simple, low-cost biomarker to aid risk stratification in the preoperative setting.
    Journal
    |
    CRP (C-reactive protein)
    3d
    GASTROBRAIN: Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer (clinicaltrials.gov)
    P=N/A, N=230, Active, not recruiting, Blokhin's Russian Cancer Research Center
    New trial
    3d
    A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=578, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
    New P3 trial
    |
    TP53 (Tumor protein P53) • FAT1 (FAT atypical cadherin 1) • NOTCH3 (Notch Receptor 3)
    |
    TP53 mutation
    |
    cisplatin • paclitaxel • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Andewei (benmelstobart)
    3d
    Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial. (PubMed, BMC Med)
    Neoadjuvant MCT combined with camrelizumab led to an increased pCR rate (54.5 vs. 16.7%) in ESCC patients compared to MCT alone. This combination therapy may offer a promising approach for enhancing cancer treatment outcomes.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab)
    4d
    KEYMAKER-U06 substudy 06B: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov)
    P1/2, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Nov 2026 --> Jun 2027
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • dexamethasone • Jiataile (sacituzumab tirumotecan) • MK-4830
    5d
    Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy. (PubMed, Cancer Discov)
    Meanwhile, two dietary metabolites, garlic-derived S-allyl-L-cysteine and cruciferous vegetable-derived indole-3-carbinol, were confirmed to improve outcomes by promoting NK cells infiltration and reversing CD8+ T cells exhaustion. In conclusion, we provide the first metabolomic roadmap for precision chemoimmunotherapy in ESCC, unifying baseline prediction, longitudinal surveillance, and dietary modulation into clinically actionable paradigm.
    Journal • Metabolomic study
    |
    CD8 (cluster of differentiation 8)
    5d
    PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis. (PubMed, Clin Cancer Res)
    Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr)
    5d
    Construction of circadian clock signature for tumor microenvironment in predicting survival of esophageal squamous cell carcinoma. (PubMed, Front Immunol)
    This research illustrated the prognostic significance of seven DE-CCGs for ESCC patients based on tumor progression and immune infiltration. And the CST3 may serve as an independent prognostic biomarker and a potential therapeutic target for ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    PD-L1 expression
    5d
    Construction and validation of a novel diagnostic model for esophageal squamous cell carcinoma: an integrated analysis of multi-omics data. (PubMed, Front Immunol)
    We developed an ESCC diagnostic model and identified BID, CBX3, ECT2, KIF14, and SORBS2 as robust ESCC biomarkers. SORBS2 is a tumor-suppressor gene predominantly expressed in myofibroblasts.
    Journal
    |
    CBX3 (Chromobox 3)